Replies to post #197778 on Biotech Values

[biomaven0]

>>not sure if poly-morph patents fall under the formulation umbrella

I'd put them in a different category, because with formulation patents there is usually a way around them, while valid polymorph patents would normally be blocking. But I think they often tend to be on the weaker side.

Gleevec had some polymorph patents that if valid would have given Novartis another three years exclusivity, but if I recall correctly they settled with only a modest extension of exclusivity until some time next year. So that strongly suggests they weren't very confident in their validity.

Petyer